08:48 EDT Nektar (NKTR) jumps 130% to $21.90 after atopic dermatitis study success
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar Therapeutics Announces Positive Phase 2b Trial Results
- Nektar’s rezpegaldesleukin meets endpoints in Phase 2b atopic dermatitis trial
- Closing Bell Movers: Futures up on Iran/Israel truce, KB Home slips on outlook
- Nektar to announce induction period in REZOLVE-AD study of Rezpegaldesleukin
- Upcoming Stock Splits This Week (June 9 to June 13) – Stay Invested